InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition.
With our long history in the industry, we provide more than 5,500+ research and publications.
Research title with ★ indicates InBody recommended paper.

The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease

Ohara et al.
Used Parameters : ICW, ECW, TBW, ECW/TBW

Publication Year : 2020

Country : Japan

Journal : Diabetology & Metabolic Syndrome

Sodium–glucose cotransporter 2 (SGLT2) inhibitors are an antihyperglycemic drug with diuretic action. We recently reported that the SGLT2 inhibitor dapagliflozin ameliorates extracellular volume expansion with a mild increase in urine volume. However, the impact of the pretreatment extracellular volume status on the body fluid response to SGLT2 inhibitors remains unclear. Thirty-six diabetic kidney disease (DKD) patients were treated with dapagliflozin. The body fluid volume, including intracellular water (ICW), extracellular water …
Full text